Patent · US Expired

Method of identifying a compound that selectively inhibits cytokine-stimulated T cell induced production of TNF-alpha by monocytes

US7390630B1 · kind B1 · utility

2Cited by
1References
4Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 25, 2000
Grant dateJun 24, 2008
Priority date
Expiry dateJun 23, 2022

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/102
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A method of identifying a compound with efficacy in the treatment of chronic inflammatory disease by testing the compound for an ability to selectively inhibit the ability of Tck cells to induce pro-inflammatory cytokine release from a monocyte is disclosed. The method includes pre-incubatin Tck cells with a compound to be tested, optionally resuspending the Tck cells in the absence of the test compound, co-culturing the Tck cells with monocytes, and assaying for the production of pro-inflammatory cytokines by the monocytes. The Tck cells are produced by incubating a population of T cells with one or more cytokines or the Tck cells are isolated from synovial tissue. The Tck cells have not been contacted with an anti-CD3 antibody. The ability to selectively inhibit cytokine release indicates that the compound has efficacy in the treatment of chronic inflammatory disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.